Livforsakringsaktiebolaget Skandia »

Halozyme Therapeutics shares owned by Livforsakringsaktiebolaget Skandia

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Livforsakringsaktiebolaget Skandia from 13F filings

Historical chart of Livforsakringsaktiebolaget Skandia investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Livforsakringsaktiebolaget Skandia consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Livforsakringsaktiebolaget Skandia

Quarter filed Position value Share count Share price at filing
2024-03-31 $215k 5.3k 40.63
2023-12-31 $196k 5.3k 36.96

More positions owned by Livforsakringsaktiebolaget Skandia

Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Alphabet inc-cl a Cl A (GOOGL)
Amazon (AMZN)
Facebook Inc cl a (META)
JPMorgan Chase & Co. (JPM)
Broadcom (AVGO)
Merck & co Cl A (MRK)
Johnson & Johnson (JNJ)
Oracle corp Cl A (ORCL)
Eli Lilly & Co. (LLY)
UnitedHealth (UNH)
Abbvie (ABBV)
Bank of America Corporation (BAC)

View all positions for Livforsakringsaktiebolaget Skandia

Top funds holding Halozyme Therapeutics

Vanguard Group
Artisan Partners Limited Partnership
Alliancebernstein
Jpmorgan Chase & Co
TD Asset Management
Jennifer Ranahan
Charles Schwab Investment Management
Dimensional Fund Advisors
Arrowpoint Asset Management
Goldman Sachs Group
T. Rowe Price Associates
Norges Bank Investment Management
Bank of New York Mellon
Bank of America Corporation
New York State Common Retirement Fund

View all funds holding Halozyme Therapeutics